Navigation Links
Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team
Date:7/19/2013

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. 

Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research Team. 

"We are excited to have Marshall join our team. He has had a distinguished career on Wall Street, and this experience coupled with his deep analytical skills make him an excellent addition to Royalty Pharma," said Pablo Legorreta, Founder and CEO of Royalty Pharma.

Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $10 billion in assets, Royalty Pharma owns royalty interests in 41 marketed and late stage biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's Cimzia®, Biogen Idec's Tecifidera® and Pharmacyclics' ibrutinib. Additional company information is available at royaltypharma.com.

Royalty Pharma | RP Management LLC
Investor Relations
+ 1 (212) 883-0200
ir@royaltypharma.com


'/>"/>
SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cowen Healthcare Royalty Partners Raises $1 Billion
2. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
3. Royalty Pharma Statement Regarding Elan Proposal
4. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
5. Royalty Pharma Statement Regarding Elan Law Suits
6. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
7. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Pharmasset Reports Fiscal Year End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):